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Introduction. Treatment options for local prostate recurrence after EBRT are prostatectomy, brachytherapy, criotherapy and HI-FU.
Available data for comparison on oncologic efﬁcacy and morbidity is limited.
Purpose. To report our clinical outcomes. To investigate variables associated to biochemical failure and toxicity. To review whether
it is necessary new dose constrains to OAR to improve the therapeutic index.
Methods and materials. Twenty-ﬁve men underwent SB with I-125 seeds. Six patients were treated with a pre-plan rapid strand
technique and 19with real-time approach using loose seeds. Dose prescription: 145Gy. Post implant CT dosimetrywas performed
one month later. Nineteen dosimetric parameters were prospectively recorded for each patient from the intraoperative and
postoperative dosimetry plans. Toxicity was scored according to RTOG scale. Actuarial Kaplan–Meir overall and biochemical
failure-free survival were calculated. T-test was used to compared dosimetric parameters between patients with grade ≥2 and
0–1 toxicity.
Results. Recurrences occurred later than 18 months from the EBRT (mean dose 73.6Gy). PSA before salvage brachytehrapy was
<10ng/ml in all patients. After brachytherapy, with a median follow up of 45.8 months the actuarial 5-year overall survival and
biochemical failure-free survival were 93% and 50% respectively. In total, 27% of patients presented grade 3–4 genitourinary
and/or rectal toxicity. Six patients had grade 3–4 genitourinary toxicity secondary to bulbomembranous urethral stricture. 2
patients had grade 4 rectal toxicity (one infectious bladder ﬁstula and one prostate-rectum ﬁstula secondary to rectum biopsy).
Neither dosimetric parameters nor T stage, Gleason and PSA were associated with biochemical control or development of grade
3–4 toxicity. We observed that patients with grade 3–4 genitourinary toxicity had higher bulbomembranous urethral maximal
doses (>120Gy) but it was not statistically signiﬁcant.
Conclusions. Salvage prostate brachytherapy after EBRT can be safely performed with acceptable biochemical control and toxicity.
Bulbomembranous urethra constraints should be considered.
http://dx.doi.org/10.1016/j.rpor.2013.03.484
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Objectives. The aim of this study is to determine seminal and cytogenetic alterations following treatment with ionizing radiation
in patients with prostate cancer and its association with testicular dose.
Materials and methods. We have included patients with prostate cancer undergoing radiation therapy and who maintain preserved
ejaculation. The levels of FSH, LH, testosterone, inhibin B, and semen were studied. The induced genetic damage is quantiﬁed
using the micronucleus test. For the evaluation of the dose received in patients undergoing external beam radiotherapy OSL
dosimeters were used and for patients undergoing brachytherapy dose was evaluated in a postimplant study.
Results. We present initial data from four patients, three of them treated with brachytherapy and one with external beam radio-
therapy. The follow-up is between 3 and 9 months. Levels of LH, FSH, testosterone, SHBG and inhibin were kept in the normal
limits and no variability after treatment. The sexual potency and ejaculation was preserved in all patients. The rate of micronu-
clei (MN), – chromosome damage – ranged from 2 to 14 MN/1000 binucletaed cells, maintained on the same level before and after
treatment. The median dose (D50) averaged for both testicles for patients undergoing BQT was 190mGy (range 30–520mGy). The
total dose in each testicle as a result of 38 imaging (CBCT) was 1200mGy and 38 as a result of treatment sessions was 2100mGy.
Conclusion. The results show that the doses accumulated in the testes in the patient undergoing external radiotherapy are
higher than those accumulated by the patients undergoing brachytherapy. Nevertheless, no signiﬁcant hormonal and cyto-
genetic changes were found in any of the patients. All patients retained ejaculation and sexual potency. We need more cases
and longer follow-up to assess a possible relationship between the absorbed dose in testes and fertility alterations in patients
treated with radiotherapy.
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